US12043641B2 - Minimally-invasive continuous clinical monitoring of small molecules with analytical accuracy - Google Patents

Minimally-invasive continuous clinical monitoring of small molecules with analytical accuracy Download PDF

Info

Publication number
US12043641B2
US12043641B2 US17/777,684 US202017777684A US12043641B2 US 12043641 B2 US12043641 B2 US 12043641B2 US 202017777684 A US202017777684 A US 202017777684A US 12043641 B2 US12043641 B2 US 12043641B2
Authority
US
United States
Prior art keywords
another embodiment
moiety
kit
integer
dendritic structure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US17/777,684
Other versions
US20230026678A1 (en
Inventor
Aharon Blank
Jens Anders
José VIDAL GANCEDO
Vega LLOVERAS MONSERRAT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technion Research and Development Foundation Ltd
Original Assignee
Technion Research and Development Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technion Research and Development Foundation Ltd filed Critical Technion Research and Development Foundation Ltd
Priority to US17/777,684 priority Critical patent/US12043641B2/en
Assigned to UNIVERSITAT STUTTGART reassignment UNIVERSITAT STUTTGART ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: UNIVERSITÄT ULM
Assigned to UNIVERSITAT ULM reassignment UNIVERSITAT ULM ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ANDERS, JENS
Assigned to TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED reassignment TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: UNIVERSITAT STUTTGART
Assigned to TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED reassignment TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BLANK, AHARON
Assigned to TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED reassignment TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LLOVERAS MONSERRAT, Vega, VIDAL GANCEDO, JOSE
Publication of US20230026678A1 publication Critical patent/US20230026678A1/en
Application granted granted Critical
Publication of US12043641B2 publication Critical patent/US12043641B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/65812—Cyclic phosphazenes [P=N-]n, n>=3
    • C07F9/65815—Cyclic phosphazenes [P=N-]n, n>=3 n = 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/10—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using electron paramagnetic resonance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/60—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using electron paramagnetic resonance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0001—Means for transferring electromagnetic energy to implants
    • A61F2250/0002—Means for transferring electromagnetic energy to implants for data transfer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide

Definitions

  • a dendrimer for continuously probing and quantifying an analyte is provided together with methods, kits and devices for performing sensitive, accurate and durable measurements.
  • Electrochemical methods are sensitive but present several drawbacks: a. They do not measure the glucose in the blood but rather work in the subcutaneous interstitial tissue, which negatively affects the device's sensitivity and accuracy. b. Electrochemical sensors exhibit large drifts and require frequent calibrations. c. The enzymes quickly degrade and sensors have to be replaced every 5-14 days at the latest. d. The needle with the enzyme probe must be continuously connected to an instrument or a transmitter outside the body.
  • ESR electron spin resonance
  • These include a static magnetic field, which orients the magnetic moment of the electron either parallel or anti-parallel with respect to its direction, and a microwave radiation, tuned in frequency to the energy difference between the two states which induces transitions that can be detected to characterize the sample.
  • the sample is placed in a microwave resonator, which is excited using an external high-power, high-cost microwave source and discrete electronics.
  • the high static magnetic field commonly in the 0.1-2 T range, is generated with large, power-hungry electromagnets.
  • Paramagnetic molecules as functional probes their use is far less common than e.g., florescence.
  • This invention in some embodiments thereof, relates to use of molecular binding approach using paramagnetic tags.
  • Paramagnetic tags may be measured and characterized by ESR spectrometers.
  • this invention provides a compound characterized by a dendritic structure, represented by the general Formula I: W-[B 1 ] n 0 -[B 2 ] m 1 -[B 3 ] m 2 - . . . [B g -] m g-1 -[D] h L i -G j
  • the invention further provides a device or a kit, comprising: (a) the compound as described herein; and (b) a unit comprising a compact electron spin resonance spectrometer (e.g., a compact ESR).
  • a compact electron spin resonance spectrometer e.g., a compact ESR
  • the invention further provides a method of paramagnetically monitoring an amount of a molecule within a composition, the method comprising: contacting the compound of the invention with a composition; and employing an electron spin resonance probe for monitoring the amount of said molecule.
  • the invention further provides a method for in-vivo monitoring an amount of a molecule within a bodily fluid or a tissue in a subject, comprising attaching the device or a kit of the invention to the subject, wherein attaching comprises: (a) inserting the compound into the bodily fluid or tissue; and (b) externally coupling the unit to the subject, thereby monitoring an amount of a molecule within a bodily fluid or tissue.
  • FIG. 1 is an illustration of a device and a kit for analytical-grade-accuracy minimally-invasive body chemicals measurements.
  • the Unit placed on the arm includes electron spin resonance spectrometer detecting the signal from a paramagnetic molecule that binds to the molecule of interest (e.g., glucose).
  • the paramagnetic molecule is embedded in an implantable stent placed in the blood vessel or tissue. Upon binding to the molecule of interest, the characteristics of the electron spin resonance signal of the paramagnetic molecule change, providing the ratio of bound-to-unbound molecules that leads to the glucose levels with high accuracy.
  • FIGS. 2 A-C show the operational principles of conventional commercial ESR spectrometers
  • 2 A A paramagnetic sample, e.g., a free radical with unpaired electron spin, is placed in a static magnetic field, which orients the magnetic moment of the electron either parallel or anti-parallel with respect to the direction of the field. Electromagnetic radiation, tuned in frequency to the energy difference between the two states, induces transitions that are detected to characterize the sample.
  • 2 B A typical experimental setup for ESR.
  • 2 C Close-up view of the center of the magnet, showing the resonator that focuses the microwave energy onto the sample and improves sensitivity.
  • FIG. 3 is a microphotograph and architecture of a broadband NMR spectrometer chip according to an embodiment of the invention.
  • FIG. 4 is an illustration of the unit with compact ESR spectrometer operating with the implant/stent.
  • FIGS. 5 A-B are illustrations of some embodiments of the compound-dendrimer of the invention.
  • the present invention provides, in one embodiment, a compound characterized by a dendritic structure.
  • dendritic structure it is meant that a cascade-branched, highly defined, structure which generally comprises a core, a number of generations of ramifications and an external surface.
  • the generations of ramifications are composed of repeating structural units, which radially extend outwardly from the core.
  • the external surface of a dendritic structure of a final generation is, typically, composed of the terminal functional groups (also known as “end groups”, for example, D, L, or G, as defined below) of the final generation.
  • the first-generation dendritic structure has one to nine (e.g., six) branching moieties and the number of end groups will depend on the number of ramifications of the branching moieties.
  • a second-generation dendritic structure has, e.g., additional branching moieties, and the number of end groups will depend on the number of ramifications of the branching moieties and will be raised accordingly.
  • the dendritic structure is represented by the general Formula I: W-[B 1 ] n 0 -[B 2 ] m 1 -[B 3 ] m 2 - . . . [B g -] m g-1 -[D] h L i -G j .
  • W is a core moiety. In one embodiment, W is a ring core moiety. In one embodiment, W is a ring core moiety of N 3 P 3 . In one embodiment, the compound is a dendrimer. In one embodiment, the compound is a dendrimer comprising a ring core moiety, a paramagnetic (radical) group, a linking moiety and a branching moiety.
  • the dendrimer or compound of the invention has a high affinity to an analyte within a biological specimen. In one embodiment, the dendrimer or compound of the invention is used for continuously probing and quantifying an analyte. In one embodiment, the dendrimer or compound of the invention is used for sensitive, accurate, in-vivo measurement of analytes. In one embodiment, component D is a ligand or a binding moiety of analyte G. In one embodiment, the dendrimer or compound of the invention is coupled to kits and devices for performing sensitive, accurate and durable measurements of analytes.
  • D comprises a paramagnetic group. In one embodiment, D comprises a spin-trapping group (i.e. TEMPO).
  • TEMPO spin-trapping group
  • L is a G-linking moiety.
  • G is a species selected from the group consisting: carbohydrate, cholesterol, urea, creatine, and an ion.
  • B 1 , B 2 , B 3 . . . B g are each independently a branching moiety, wherein B 1 , B 2 , B 3 . . . B g together form a dendritic structure.
  • n is an integer that equals to 1 to 9. In another embodiment, n is an integer that equals to 2 to 8. In another embodiment, n is an integer that equals to 2 to 6. In another embodiment, n is an integer that equals to 4. In another embodiment, n is an integer that equals to 6. In another embodiment, g is an integer that ranges from 1 to 14, representing the number of generations of the dendritic structure. In another embodiment, g is an integer that ranges from 1 to 10, representing the number of generations of the dendritic structure. In another embodiment, g is an integer that ranges from 2 to 8, representing the number of generations of the dendritic structure. In another embodiment, g is an integer that ranges from 1 to 3.
  • g is an integer that ranges from 1 to 2.
  • m is an integer that equals 0 to 6 representing, in each occurrence, the ramification number of each generation.
  • m is an integer that equals 1 to 6.
  • m is an integer that equals 1 to 4.
  • m is an integer that equals 1, 2, or 3.
  • h is an integer that ranges from 1 to n ⁇ m 1 ⁇ m 2 ⁇ . . . m g-1 , representing the total numbers of D in the dendritic structure.
  • i is an integer that ranges from 1 to h, representing the total numbers of L in the dendritic structure.
  • j is an integer that ranges from 0 to i, representing the total numbers of G in the dendritic structure. In another embodiment, j is greater than zero. In another embodiment, j is greater than one.
  • “ramification number” refers to the number of branches (also referred to “branching moieties”) extended outwardly from a branch of an earlier generation.
  • m 1 for example, 2. That is, when n is 6 (i.e. there are 6 branching moieties attached to W) h will have the maximum value of 12 (6 ⁇ 2), see scheme in FIG. 5 B .
  • the number of branching moieties extended outwardly from the first, second and third generations are m 1 , m 2 , and m 3 , respectively. That is, when n is 6, and e.g., each of m 1 , m 2 , and m 3 equals 2, h will have the maximum value of 48 (6 ⁇ 2 ⁇ 2 ⁇ 2).
  • L i.e. G-linking moiety
  • each of the functional groups being independently selected from, without being limited thereto, hydroxyl, chlorine, and amino acid.
  • D is a radical. In another embodiment, D is a mono radical. In another embodiment, D is a diradical. In another embodiment, D is a triradical.
  • L is a ligand of a body sample.
  • D is a ligand of a molecule present in a living organ.
  • L is a ligand of a bodily fluid constituent (such as blood, urine, semen, or saliva).
  • bodily fluid is expelled bodily fluid.
  • L has a high affinity to a bodily fluid constituent.
  • L has a high affinity to a blood constituent.
  • L has a high affinity to a plasma constituent.
  • L is a ligand of a carbohydrate.
  • L is a ligand of glucose.
  • L is a ligand of an alcohol.
  • L is a ligand of ethanol.
  • L is a ligand of a bacterial toxin.
  • L is a ligand of bacterial or a viral component.
  • a radical group is derived from a nitroso group.
  • a radical group is derived from a perchlorotriphenylmethyl radical.
  • a radical group comprises a trityl radical.
  • D comprises a trityl radical.
  • a radical group or D comprises a perchlorotriphenylmethyl (PTM) radical.
  • radical group or D comprises a nitroso radical.
  • a spin-trapping group or D comprises a tetramethylpiperidin-1-yl)oxyl (TEMPO).
  • a radical group is derived from a Doxil radical.
  • a radical group is derived from a picrylhydrazyl radical.
  • a radical group is derived from a Proxil radical.
  • a radical group is derived from a Galvinoxyl radical.
  • a radical group is derived from a,3-bisdiphenylene-2-phenylallyl (BDPA) radical.
  • Further non-limiting exemplary radicals are selected from alpha-phenyl N-tertiary-butyl nitrone (PBN), 5,5-dimethyl-pyrroline N-oxide (DMPO), 5-Diisopropoxyphosphoryl-5-methyl-1-pyrroline-N-oxide (DIPPMPO).
  • said G-linking moiety comprises a boronic acid moiety.
  • core moiety comprises a phosphorus-containing ring.
  • branching moiety is further attached to a linking moiety.
  • the moiety may link an end of said branching moiety to an additional branching moiety.
  • the linking moiety comprises an aldehyde.
  • branching moiety comprises at least one phosphorus atom.
  • branching moiety comprises 1 to 5 phosphorus atoms.
  • branching moiety comprises 2 to 4 phosphorus atoms.
  • branching moiety comprises 1 to 3 phosphorus atoms.
  • branching moiety comprises 1 phosphorus atom.
  • branching moiety comprises 2 phosphorus atoms.
  • a compound as described herein is a phosphorus dendrimer. In another embodiment, a compound as described herein is a phosphorus dendrimer based on a cyclotriphosphazene core, TEMPO, or PTM radicals. In another embodiment, a compound as described herein is a phosphorus dendrimer based on a cyclotriphosphazene core, TEMPO, or PTM radicals and boronic acid as glucose-receptor moiety.
  • the device/kit of the invention selectively recognizes glucose and the ESR signal changes depending on the number of glucose molecules bound to the compound as described herein.
  • synthesis of phosphorus-comprising dendrimers involves two synthetic steps: starting from hexachlorocyclotryphosphazene, with p-hydroxybenzaldehyde in basic media, Gc0′ is obtained, which in a second step reacts with dichlorophosphonomethylhydrazide to obtain the next generation ending in chlorine (Gc1) that reacts again with p-hydroxybenzaldehyde to obtain the next generation ending in aldehyde (Gc1′), and so on with the following generations.
  • zero- or first-order dendrimer generations capped by chlorine are used.
  • an amino acid as spacer binds both the radical and the analyte (such as glucose) binding molecule to the dendrimer: for example, a TEMPO radical with an acid functional group and a boronic acid derivative functionalized with an amino group ( FIG. 5 A ).
  • a device or a kit comprising: (a) the compound as described herein; and (b) a unit comprising an electron spin resonance spectrometer.
  • An electron spin resonance (ESR) spectrometer is also referred to as “Electron paramagnetic resonance (EPR) spectrometer”.
  • ESR electron spin resonance
  • EPR Electro paramagnetic resonance
  • the compound as described herein is coupled to a stent.
  • the compound as described herein is adhered to a stent.
  • the compound as described herein coats at least one surface of a stent.
  • the compound as described herein coats at least one outer-surface of a stent.
  • the stent is an intra-arterial stent, or in the interstitial tissue.
  • a device or a kit comprising a resonant radio-frequency coil.
  • the stent comprises a resonant radio-frequency coil.
  • a device or a kit comprising a microwave pulse antenna.
  • the stent comprises a microwave pulse antenna.
  • the compound as described herein is in contact with the antenna, the resonant radio-frequency coil, or both.
  • the compound coats at least one surface of the antenna.
  • the compound coats at least one outer-surface of the antenna.
  • the electron spin resonance spectrometer is coupled to an electron spin resonance receiver adapted to receive a microwave pulse from the antenna.
  • the unit comprises an electron spin resonance receiver.
  • the electron spin resonance receiver is wirelessly connected to the electron spin resonance spectrometer and/or to the antenna.
  • the electron spin resonance receiver is wirelessly connected to the antenna.
  • the stent comprises the electron spin resonance receiver.
  • the electron spin resonance receiver is positioned outside the stent.
  • the device comprises the electron spin resonance receiver.
  • the stent comprises the antenna.
  • the unit comprises the electron spin resonance spectrometer.
  • the device is coupled with a pulse spectrometer. Pulse spectrometer may allow to generate pulses with arbitrary shape and phase.
  • the unit comprises a magnet.
  • the electron spin resonance spectrometer is coupled to a magnet.
  • the unit comprises a magnet.
  • the electron spin resonance spectrometer is physically connected to a magnet.
  • the magnet is a static magnet.
  • the magnet is configured to create a homogenous field at the location of the antenna.
  • the magnet comprises samarium cobalt.
  • the unit, the device or the kit further comprises a power source.
  • the unit, the device or the kit further comprises a computing unit for calculating and providing data such as concentration or amount of an analyte, based on measurements or based on binding events of the analyte or G to component L.
  • a method of monitoring an amount or a concentration of a molecule within a composition in another embodiment, provided herein a method of monitoring an amount or a concentration of a molecule within a composition.
  • a method of monitoring a concentration of a molecule within a composition In another embodiment, provided herein a method of paramagnetically monitoring an amount of a molecule within a composition. In another embodiment, provided herein a method of paramagnetically monitoring a concentration of a molecule within a composition.
  • “paramagnetically monitoring” refers to using ESR for indirectly detecting species that is not paramagnetic.
  • the monitoring is performed through coupling the species to an ESR-measurable paramagnetic species.
  • a method as described herein comprises: contacting the compound of the invention with a composition susceptible of comprising a molecule; and employing an electron spin resonance probe for monitoring the amount of the molecule within the composition.
  • the composition is a bodily fluid. In another embodiment, the composition comprises a biopsy interstitial tissue. In another embodiment, the composition comprises cells. In another embodiment, the composition comprises a bodily fluid. In another embodiment, the composition comprises blood. In another embodiment, the composition comprises a biological specimen. In another embodiment, the composition comprises an organic molecule. In another embodiment, the composition comprises a protein. In another embodiment, the composition comprises a carbohydrate. In another embodiment, the molecule is selected from the group consisting: an organic molecule, a protein, a carbohydrate, cholesterol, urea, creatine, and an ion. In another embodiment, the molecule is glucose.
  • monitoring is in-vivo monitoring. In another embodiment, monitoring is ex-vivo monitoring. In another embodiment, monitoring is in-situ monitoring.
  • a method for in-vivo monitoring an amount and/or a concentration of a molecule within a bodily fluid in a subject comprising attaching the device or a kit of the invention to a subject, wherein attaching comprises: (a) inserting the compound as described herein into a biological specimen such as a bodily fluid and (b) externally coupling the unit to the subject, thereby monitoring an amount of a molecule within a bodily fluid.
  • attaching comprises: (a) inserting the compound as described herein into a biological specimen such as a bodily fluid and (b) externally coupling the unit to the subject, thereby monitoring an amount of a molecule within a bodily fluid.
  • externally coupling the unit to the subject is securing the unit to the subject's cloths.
  • externally coupling the unit to the subject is externally securing the unit to the subject's arms or legs.
  • a method for monitoring an amount or a concentration of a molecule within a biological specimen comprising: (a) contacting the compound of the invention with the biological specimen; and (b) coupling the unit as described herein with the molecule, thereby monitoring an amount or a concentration of a molecule within a bodily fluid.
  • a method for monitoring an amount or a concentration of a molecule within a biological specimen comprising: (a) contacting the compound of the invention with the biological specimen, wherein the compound of the invention is coupled an electron spin resonance spectrometer; and (b) coupling the receiver as described herein with the spectrometer, thereby monitoring an amount or a concentration of a molecule within a bodily fluid.
  • the unit comprising the electron spin resonance spectrometer is placed on a body part such as the arm to detect the signal from a paramagnetic molecule that binds to the molecule of interest (e.g., glucose).
  • the paramagnetic molecule is embedded in an implantable stent placed in a blood vessel or tissue.
  • the characteristics of the electron spin resonance signal of the paramagnetic molecule change, providing the ratio of bound-to-unbound molecules that leads to the glucose levels with high accuracy.
  • the stent or implant of the invention comprises a wire or a metal wire coated with a compound of the invention. In one embodiment, the stent or implant of the invention provides an accurate continuous monitoring of small-molecule concentration (such as but not limited to glucose).
  • the stent or implant of the invention comprises an implantable radio-frequency coil that is embedded in a stent-like structure inside a tissue or a blood vessel, coated with compound (dendrimer) of the invention.
  • monitoring as described herein (bound or unbound) is based on electron spin resonance (ESR) signal (see FIG. 2 ).
  • ESR electron spin resonance
  • electromagnetic waves are used, and can penetrate the skin and the bloodstream thus providing high accuracy spectroscopic data without any other interfering signals.
  • the stent/implantable device serves both as a scaffold for holding the compound of the invention in a stable manner in the bloodstream, as well as facilitate the coupling of external radio-frequency (RF) radiation required for the ESR measurement into a miniature tuned resonant RF coil that will be an integral part of the stent-like device structure.
  • RF radio-frequency
  • the stent or implant of the invention comprises an implantable RF antenna coated with a compound of the invention.
  • the implantable RF antenna comprises a memory alloy.
  • the implantable RF antenna comprises nitinol.
  • the magnet provides a static field of ⁇ 700 G external to the magnet structure ( ⁇ 5 mm below the magnet surface) with homogeneity of ⁇ 0.1% for a region of 0.5 to 20 mm.
  • the static magnetic field covers a relevant volume in a blood vessel.
  • spectrometer is a miniature ESR spectrometer. In one embodiment, spectrometer is within the working range of 2 GHz ⁇ 20% (corresponding to the static field of 700 G).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A dendrimer including a ring core moiety, a paramagnetic group, a linking moiety and a branching moiety for continuously probing and quantifying an analyte is provided together with methods, kits and devices for performing sensitive, accurate and durable measurements.

Description

CROSS REFERENCE TO RELATED APPLICATIONS
This application is a National Phase of PCT Patent Application No. PCT/IL2020/051197 having International filing date of Nov. 18, 2020, which claims the benefit of priority under 35 U.S.C. § 119(e) of U.S. Provisional Patent Application No. 62/936,689, filed on Nov. 18, 2019, titled “MINIMALLY-INVASIVE CONTINUOUS CLINICAL MONITORING OF SMALL MOLECULES WITH ANALYTICAL ACCURACY”, the contents of which are all incorporated by reference as if fully set forth herein in their entirety.
FIELD OF THE INVENTION
A dendrimer for continuously probing and quantifying an analyte is provided together with methods, kits and devices for performing sensitive, accurate and durable measurements.
BACKGROUND OF THE INVENTION
Sensors for the continuous and accurate monitoring of small molecules in the body, such as glucose, are required technologies in the field of medical devices. The leading approach for small molecules sensing makes use of electrochemical methods using a chemical or an enzyme that reacts with the molecule of interest and generate product that can be detected electrochemically. Electrochemical methods are sensitive but present several drawbacks: a. They do not measure the glucose in the blood but rather work in the subcutaneous interstitial tissue, which negatively affects the device's sensitivity and accuracy. b. Electrochemical sensors exhibit large drifts and require frequent calibrations. c. The enzymes quickly degrade and sensors have to be replaced every 5-14 days at the latest. d. The needle with the enzyme probe must be continuously connected to an instrument or a transmitter outside the body.
In order to improve the life span of continuous glucose-monitoring implants, researchers are currently trying to move away from methods that use exogenous molecules that react with the small molecules of interest (e.g., glucose). This trend has recently led towards methods in which newly synthesized fluorescent molecular with components (e.g., synthetic lectins) that reversibly bind to the molecule of interest and where these binding events are then detected using optical methods. This results in fairly large, full-of-electronics, centimeter-sized implants that cannot be placed in the bloodstream and thus suffer from many of the above-mentioned drawbacks of the subcutaneously-placed electrochemical needles. Furthermore, optical methods are fairly non-specific (meaning that many molecules present fluorescence) and thus the fluorescence signal can be affected by the environment, leading to significant measurement noise over real analyte-to-be-detected concentration values.
One of the reasons for the limited range of functional paramagnetic species available is the relatively high complexity, size and cost of electron spin resonance (ESR) systems needed to detect them (compared to relatively compact fluorescence systems, for example), and their more complex chemistry.
These include a static magnetic field, which orients the magnetic moment of the electron either parallel or anti-parallel with respect to its direction, and a microwave radiation, tuned in frequency to the energy difference between the two states which induces transitions that can be detected to characterize the sample.
In classical ESR detection setups, the sample is placed in a microwave resonator, which is excited using an external high-power, high-cost microwave source and discrete electronics. The high static magnetic field, commonly in the 0.1-2 T range, is generated with large, power-hungry electromagnets. Paramagnetic molecules as functional probes their use is far less common than e.g., florescence.
Although recently commercial benchtop and academic prototypes of point-of-care ESR spectrometers have become available, these devices all work in the so-called continuous-wave mode, their size is still in the order of 10s of cm, their weight is several 10s of kgs, their cost is several 10s of k€s, and their power consumption is still in the range of hundreds of Watts.
SUMMARY OF THE INVENTION
This invention, in some embodiments thereof, relates to use of molecular binding approach using paramagnetic tags. Paramagnetic tags may be measured and characterized by ESR spectrometers.
In one embodiment, this invention provides a compound characterized by a dendritic structure, represented by the general Formula I: W-[B1]n 0-[B2]m 1-[B3]m 2- . . . [Bg-]m g-1-[D]hLi-Gj
wherein:
    • W is a core moiety (e.g., a ring moiety);
    • D comprises a paramagnetic (e.g., free radical) group (e.g., TEMPO);
    • L is a G-linking moiety;
    • G is a species selected from the group consisting: carbohydrate, cholesterol, urea, creatine, and an ion;
    • B1, B2, B3 . . . Bg are each independently a branching moiety, wherein B1, B2, B3 . . . Bg together form said dendritic structure;
    • n is an integer that equals to 2 to 6,
    • g is an integer that ranges from 1 to 10, representing the number of generations of said dendritic structure.
    • m is an integer that equals 1, 2, or 3 representing, in each occurrence, the ramification number of each generation;
    • h is an integer that ranges from 1 to n×m1×m2× . . . mg-1, representing the total numbers of D in said dendritic structure;
    • i is an integer that ranges from 1 to h, representing the total numbers of L in said dendritic structure, and
    • j is an integer that ranges from 0 to i, representing the total numbers of G in said dendritic structure. In one embodiment, G-linking moiety comprises one or more functional groups. In one embodiment, D is a radical. In one embodiment, the core moiety comprises a phosphorus-containing ring.
In another embodiment, the invention further provides a device or a kit, comprising: (a) the compound as described herein; and (b) a unit comprising a compact electron spin resonance spectrometer (e.g., a compact ESR).
In another embodiment, the invention further provides a method of paramagnetically monitoring an amount of a molecule within a composition, the method comprising: contacting the compound of the invention with a composition; and employing an electron spin resonance probe for monitoring the amount of said molecule.
In another embodiment, the invention further provides a method for in-vivo monitoring an amount of a molecule within a bodily fluid or a tissue in a subject, comprising attaching the device or a kit of the invention to the subject, wherein attaching comprises: (a) inserting the compound into the bodily fluid or tissue; and (b) externally coupling the unit to the subject, thereby monitoring an amount of a molecule within a bodily fluid or tissue.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is an illustration of a device and a kit for analytical-grade-accuracy minimally-invasive body chemicals measurements. The Unit placed on the arm includes electron spin resonance spectrometer detecting the signal from a paramagnetic molecule that binds to the molecule of interest (e.g., glucose). The paramagnetic molecule is embedded in an implantable stent placed in the blood vessel or tissue. Upon binding to the molecule of interest, the characteristics of the electron spin resonance signal of the paramagnetic molecule change, providing the ratio of bound-to-unbound molecules that leads to the glucose levels with high accuracy.
FIGS. 2A-C show the operational principles of conventional commercial ESR spectrometers (2A) A paramagnetic sample, e.g., a free radical with unpaired electron spin, is placed in a static magnetic field, which orients the magnetic moment of the electron either parallel or anti-parallel with respect to the direction of the field. Electromagnetic radiation, tuned in frequency to the energy difference between the two states, induces transitions that are detected to characterize the sample. (2B) A typical experimental setup for ESR. (2C) Close-up view of the center of the magnet, showing the resonator that focuses the microwave energy onto the sample and improves sensitivity.
FIG. 3 is a microphotograph and architecture of a broadband NMR spectrometer chip according to an embodiment of the invention.
FIG. 4 is an illustration of the unit with compact ESR spectrometer operating with the implant/stent.
FIGS. 5A-B Are illustrations of some embodiments of the compound-dendrimer of the invention.
 DETAILED DESCRIPTION OF THE INVENTION
The present invention provides, in one embodiment, a compound characterized by a dendritic structure.
In one embodiment, by “dendritic structure” it is meant that a cascade-branched, highly defined, structure which generally comprises a core, a number of generations of ramifications and an external surface.
In one embodiment, the generations of ramifications are composed of repeating structural units, which radially extend outwardly from the core. The external surface of a dendritic structure of a final generation is, typically, composed of the terminal functional groups (also known as “end groups”, for example, D, L, or G, as defined below) of the final generation. The first-generation dendritic structure has one to nine (e.g., six) branching moieties and the number of end groups will depend on the number of ramifications of the branching moieties. A second-generation dendritic structure has, e.g., additional branching moieties, and the number of end groups will depend on the number of ramifications of the branching moieties and will be raised accordingly. In one embodiment, the dendritic structure is represented by the general Formula I: W-[B1]n 0-[B2]m 1-[B3]m 2- . . . [Bg-]m g-1-[D]hLi-Gj.
In one embodiment, W is a core moiety. In one embodiment, W is a ring core moiety. In one embodiment, W is a ring core moiety of N3P3. In one embodiment, the compound is a dendrimer. In one embodiment, the compound is a dendrimer comprising a ring core moiety, a paramagnetic (radical) group, a linking moiety and a branching moiety.
In one embodiment, the dendrimer or compound of the invention has a high affinity to an analyte within a biological specimen. In one embodiment, the dendrimer or compound of the invention is used for continuously probing and quantifying an analyte. In one embodiment, the dendrimer or compound of the invention is used for sensitive, accurate, in-vivo measurement of analytes. In one embodiment, component D is a ligand or a binding moiety of analyte G. In one embodiment, the dendrimer or compound of the invention is coupled to kits and devices for performing sensitive, accurate and durable measurements of analytes.
In one embodiment, D comprises a paramagnetic group. In one embodiment, D comprises a spin-trapping group (i.e. TEMPO).
In one embodiment, L is a G-linking moiety.
In one embodiment, G is a species selected from the group consisting: carbohydrate, cholesterol, urea, creatine, and an ion.
In one embodiment, B1, B2, B3 . . . Bg are each independently a branching moiety, wherein B1, B2, B3 . . . Bg together form a dendritic structure.
In another embodiment, n is an integer that equals to 1 to 9. In another embodiment, n is an integer that equals to 2 to 8. In another embodiment, n is an integer that equals to 2 to 6. In another embodiment, n is an integer that equals to 4. In another embodiment, n is an integer that equals to 6. In another embodiment, g is an integer that ranges from 1 to 14, representing the number of generations of the dendritic structure. In another embodiment, g is an integer that ranges from 1 to 10, representing the number of generations of the dendritic structure. In another embodiment, g is an integer that ranges from 2 to 8, representing the number of generations of the dendritic structure. In another embodiment, g is an integer that ranges from 1 to 3. In another embodiment, g is an integer that ranges from 1 to 2. In another embodiment, m is an integer that equals 0 to 6 representing, in each occurrence, the ramification number of each generation. In another embodiment, m is an integer that equals 1 to 6. In another embodiment, m is an integer that equals 1 to 4. In another embodiment, m is an integer that equals 1, 2, or 3. In another embodiment, h is an integer that ranges from 1 to n×m1×m2× . . . mg-1, representing the total numbers of D in the dendritic structure. In another embodiment, i is an integer that ranges from 1 to h, representing the total numbers of L in the dendritic structure. In another embodiment, j is an integer that ranges from 0 to i, representing the total numbers of G in the dendritic structure. In another embodiment, j is greater than zero. In another embodiment, j is greater than one.
Herein, “ramification number” refers to the number of branches (also referred to “branching moieties”) extended outwardly from a branch of an earlier generation. For example, when the dendritic structure has two generations (g=2), the number of branching moieties extended outwardly from a branch of the first generation is m1, for example, 2. That is, when n is 6 (i.e. there are 6 branching moieties attached to W) h will have the maximum value of 12 (6×2), see scheme in FIG. 5B.
For yet another example, when the dendritic structure has four generations (g=4), the number of branching moieties extended outwardly from the first, second and third generations are m1, m2, and m3, respectively. That is, when n is 6, and e.g., each of m1, m2, and m3 equals 2, h will have the maximum value of 48 (6×2×2×2).
In another embodiment, L (i.e. G-linking moiety) comprises one or more functional groups. In another embodiment, each of the functional groups being independently selected from, without being limited thereto, hydroxyl, chlorine, and amino acid.
In another embodiment, D is a radical. In another embodiment, D is a mono radical. In another embodiment, D is a diradical. In another embodiment, D is a triradical.
In another embodiment, L is a ligand of a body sample. In another embodiment, D is a ligand of a molecule present in a living organ. In another embodiment, L is a ligand of a bodily fluid constituent (such as blood, urine, semen, or saliva). In another embodiment, bodily fluid is expelled bodily fluid. In another embodiment, L has a high affinity to a bodily fluid constituent. In another embodiment, L has a high affinity to a blood constituent. In another embodiment, L has a high affinity to a plasma constituent. In another embodiment, L is a ligand of a carbohydrate. In another embodiment, L is a ligand of glucose. In another embodiment, L is a ligand of an alcohol. In another embodiment, L is a ligand of ethanol. In another embodiment, L is a ligand of a bacterial toxin. In another embodiment, L is a ligand of bacterial or a viral component.
In another embodiment, a radical group is derived from a nitroso group. In another embodiment, a radical group is derived from a perchlorotriphenylmethyl radical. In another embodiment, a radical group comprises a trityl radical. In another embodiment, D comprises a trityl radical. In another embodiment, a radical group or D comprises a perchlorotriphenylmethyl (PTM) radical. In another embodiment, radical group or D comprises a nitroso radical. In another embodiment, a spin-trapping group or D comprises a tetramethylpiperidin-1-yl)oxyl (TEMPO). In another embodiment, a radical group is derived from a Doxil radical. In another embodiment, a radical group is derived from a picrylhydrazyl radical. In another embodiment, a radical group is derived from a Proxil radical. In another embodiment, a radical group is derived from a Galvinoxyl radical. In another embodiment, a radical group is derived from a,3-bisdiphenylene-2-phenylallyl (BDPA) radical. Further non-limiting exemplary radicals are selected from alpha-phenyl N-tertiary-butyl nitrone (PBN), 5,5-dimethyl-pyrroline N-oxide (DMPO), 5-Diisopropoxyphosphoryl-5-methyl-1-pyrroline-N-oxide (DIPPMPO).
In another embodiment, said G-linking moiety comprises a boronic acid moiety. In another embodiment, core moiety comprises a phosphorus-containing ring.
In another embodiment, branching moiety is further attached to a linking moiety. The moiety may link an end of said branching moiety to an additional branching moiety. In another embodiment, the linking moiety comprises an aldehyde. In another embodiment, branching moiety comprises at least one phosphorus atom. In another embodiment, branching moiety comprises 1 to 5 phosphorus atoms. In another embodiment, branching moiety comprises 2 to 4 phosphorus atoms. In another embodiment, branching moiety comprises 1 to 3 phosphorus atoms. In another embodiment, branching moiety comprises 1 phosphorus atom. In another embodiment, branching moiety comprises 2 phosphorus atoms.
In another embodiment, a compound as described herein is a phosphorus dendrimer. In another embodiment, a compound as described herein is a phosphorus dendrimer based on a cyclotriphosphazene core, TEMPO, or PTM radicals. In another embodiment, a compound as described herein is a phosphorus dendrimer based on a cyclotriphosphazene core, TEMPO, or PTM radicals and boronic acid as glucose-receptor moiety.
In another embodiment, the device/kit of the invention selectively recognizes glucose and the ESR signal changes depending on the number of glucose molecules bound to the compound as described herein.
In another embodiment, synthesis of phosphorus-comprising dendrimers involves two synthetic steps: starting from hexachlorocyclotryphosphazene, with p-hydroxybenzaldehyde in basic media, Gc0′ is obtained, which in a second step reacts with dichlorophosphonomethylhydrazide to obtain the next generation ending in chlorine (Gc1) that reacts again with p-hydroxybenzaldehyde to obtain the next generation ending in aldehyde (Gc1′), and so on with the following generations. In another embodiment, zero- or first-order dendrimer generations capped by chlorine, are used. In another embodiment, an amino acid as spacer binds both the radical and the analyte (such as glucose) binding molecule to the dendrimer: for example, a TEMPO radical with an acid functional group and a boronic acid derivative functionalized with an amino group (FIG. 5A).
Devices and Kits
In another embodiment, provided herein a device or a kit, comprising: (a) the compound as described herein; and (b) a unit comprising an electron spin resonance spectrometer. An electron spin resonance (ESR) spectrometer is also referred to as “Electron paramagnetic resonance (EPR) spectrometer”. In another embodiment, the compound as described herein is coupled to a stent. In another embodiment, the compound as described herein is adhered to a stent. In another embodiment, the compound as described herein coats at least one surface of a stent. In another embodiment, the compound as described herein coats at least one outer-surface of a stent. In another embodiment, the stent is an intra-arterial stent, or in the interstitial tissue.
In another embodiment, provided a device or a kit comprising a resonant radio-frequency coil. In another embodiment, the stent comprises a resonant radio-frequency coil. In another embodiment, provided a device or a kit comprising a microwave pulse antenna. In another embodiment, the stent comprises a microwave pulse antenna. In another embodiment, the compound as described herein is in contact with the antenna, the resonant radio-frequency coil, or both. In another embodiment, the compound coats at least one surface of the antenna. In another embodiment, the compound coats at least one outer-surface of the antenna.
In another embodiment, the electron spin resonance spectrometer is coupled to an electron spin resonance receiver adapted to receive a microwave pulse from the antenna. In another embodiment, the unit comprises an electron spin resonance receiver. In another embodiment, the electron spin resonance receiver is wirelessly connected to the electron spin resonance spectrometer and/or to the antenna. In another embodiment, the electron spin resonance receiver is wirelessly connected to the antenna. In another embodiment, the stent comprises the electron spin resonance receiver. In another embodiment, the electron spin resonance receiver is positioned outside the stent.
In another embodiment, the device comprises the electron spin resonance receiver. In another embodiment, the stent comprises the antenna. In another embodiment, the unit comprises the electron spin resonance spectrometer. In another embodiment, the device is coupled with a pulse spectrometer. Pulse spectrometer may allow to generate pulses with arbitrary shape and phase.
In another embodiment, the unit comprises a magnet. In another embodiment, the electron spin resonance spectrometer is coupled to a magnet. In another embodiment, the unit comprises a magnet. In another embodiment, the electron spin resonance spectrometer is physically connected to a magnet. In another embodiment, the magnet is a static magnet. In another embodiment, the magnet is configured to create a homogenous field at the location of the antenna. In another embodiment, the magnet comprises samarium cobalt.
In another embodiment, the unit, the device or the kit further comprises a power source. In another embodiment, the unit, the device or the kit further comprises a computing unit for calculating and providing data such as concentration or amount of an analyte, based on measurements or based on binding events of the analyte or G to component L.
Methods
In another embodiment, provided herein a method of monitoring an amount or a concentration of a molecule within a composition.
In another embodiment, provided herein a method of monitoring a concentration of a molecule within a composition. In another embodiment, provided herein a method of paramagnetically monitoring an amount of a molecule within a composition. In another embodiment, provided herein a method of paramagnetically monitoring a concentration of a molecule within a composition.
In another embodiment, “paramagnetically monitoring” refers to using ESR for indirectly detecting species that is not paramagnetic. In another embodiment, the monitoring is performed through coupling the species to an ESR-measurable paramagnetic species. In another embodiment, a method as described herein comprises: contacting the compound of the invention with a composition susceptible of comprising a molecule; and employing an electron spin resonance probe for monitoring the amount of the molecule within the composition.
In another embodiment, the composition is a bodily fluid. In another embodiment, the composition comprises a biopsy interstitial tissue. In another embodiment, the composition comprises cells. In another embodiment, the composition comprises a bodily fluid. In another embodiment, the composition comprises blood. In another embodiment, the composition comprises a biological specimen. In another embodiment, the composition comprises an organic molecule. In another embodiment, the composition comprises a protein. In another embodiment, the composition comprises a carbohydrate. In another embodiment, the molecule is selected from the group consisting: an organic molecule, a protein, a carbohydrate, cholesterol, urea, creatine, and an ion. In another embodiment, the molecule is glucose.
In another embodiment, monitoring is in-vivo monitoring. In another embodiment, monitoring is ex-vivo monitoring. In another embodiment, monitoring is in-situ monitoring.
In another embodiment, provided herein a method for in-vivo monitoring an amount and/or a concentration of a molecule within a bodily fluid in a subject, comprising attaching the device or a kit of the invention to a subject, wherein attaching comprises: (a) inserting the compound as described herein into a biological specimen such as a bodily fluid and (b) externally coupling the unit to the subject, thereby monitoring an amount of a molecule within a bodily fluid. In another embodiment, externally coupling the unit to the subject is securing the unit to the subject's cloths. In another embodiment, externally coupling the unit to the subject is externally securing the unit to the subject's arms or legs.
In another embodiment, provided herein a method for monitoring an amount or a concentration of a molecule within a biological specimen, comprising: (a) contacting the compound of the invention with the biological specimen; and (b) coupling the unit as described herein with the molecule, thereby monitoring an amount or a concentration of a molecule within a bodily fluid. In another embodiment, provided herein a method for monitoring an amount or a concentration of a molecule within a biological specimen, comprising: (a) contacting the compound of the invention with the biological specimen, wherein the compound of the invention is coupled an electron spin resonance spectrometer; and (b) coupling the receiver as described herein with the spectrometer, thereby monitoring an amount or a concentration of a molecule within a bodily fluid.
In one embodiment, as provided in FIG. 1 the unit comprising the electron spin resonance spectrometer is placed on a body part such as the arm to detect the signal from a paramagnetic molecule that binds to the molecule of interest (e.g., glucose). In one embodiment, the paramagnetic molecule is embedded in an implantable stent placed in a blood vessel or tissue. In one embodiment, upon binding to the molecule of interest, the characteristics of the electron spin resonance signal of the paramagnetic molecule change, providing the ratio of bound-to-unbound molecules that leads to the glucose levels with high accuracy.
In one embodiment, the stent or implant of the invention comprises a wire or a metal wire coated with a compound of the invention. In one embodiment, the stent or implant of the invention provides an accurate continuous monitoring of small-molecule concentration (such as but not limited to glucose).
In one embodiment, the stent or implant of the invention comprises an implantable radio-frequency coil that is embedded in a stent-like structure inside a tissue or a blood vessel, coated with compound (dendrimer) of the invention. In one embodiment, monitoring as described herein (bound or unbound) is based on electron spin resonance (ESR) signal (see FIG. 2 ). In one embodiment, electromagnetic waves are used, and can penetrate the skin and the bloodstream thus providing high accuracy spectroscopic data without any other interfering signals. In one embodiment, the stent/implantable device serves both as a scaffold for holding the compound of the invention in a stable manner in the bloodstream, as well as facilitate the coupling of external radio-frequency (RF) radiation required for the ESR measurement into a miniature tuned resonant RF coil that will be an integral part of the stent-like device structure.
In one embodiment, the stent or implant of the invention comprises an implantable RF antenna coated with a compound of the invention. In one embodiment, the implantable RF antenna comprises a memory alloy. In one embodiment, the implantable RF antenna comprises nitinol.
In one embodiment, the magnet provides a static field of ˜700 G external to the magnet structure (˜5 mm below the magnet surface) with homogeneity of ˜0.1% for a region of 0.5 to 20 mm. In one embodiment, the static magnetic field covers a relevant volume in a blood vessel.
In one embodiment, spectrometer is a miniature ESR spectrometer. In one embodiment, spectrometer is within the working range of 2 GHz±20% (corresponding to the static field of 700 G).

Claims (9)

What is claimed is:
1. A kit, comprising: (a) a paramagnetic tag; and (b) a unit comprising an electron spin resonance spectrometer; wherein the paramagnetic tag has a dendritic structure, represented by the general Formula I:

W-[B1]n 0-[B2]m 1-[B3]m 2- . . . [Bg-]m g-1-[D]hLi-Gj
wherein:
W is a ring core moiety;
D comprises a spin-trapping group;
L is a G-linking moiety;
G is a species selected from the group consisting: carbohydrate, cholesterol, urea, creatine, and an ion;
B1, B2, B3 . . . Bg are each independently a branching moiety, wherein B1, B2, B3 . . . Bg together form a dendritic structure;
n is an integer that equals to 2 to 6;
g is an integer that ranges from 1 to 10, representing the number of generations of said dendritic structure;
m is an integer that equals 1, 2, or 3 representing, in each occurrence, the ramification number of each generation;
h is an integer that ranges from 1 to n×m1×m2× . . . mg-1, representing the total numbers of D in said dendritic structure;
i is an integer that ranges from 1 to h, representing the total numbers of L in said dendritic structure, and
j is an integer that ranges from 0 to i, representing the total numbers of G in said dendritic structure.
2. The kit of claim 1, wherein said compound is coupled to an intra-arterial stent.
3. The kit of claim 1, comprising a resonant radio-frequency coil, a microwave pulse antenna, or both.
4. The kit of claim 1, comprising a microwave pulse antenna wherein a surface of said antenna is coated with said compound.
5. The kit of claim 1, wherein said electron spin resonance spectrometer is coupled to an electron spin resonance receiver adapted to receive a microwave pulse from said antenna.
6. The kit of claim 1, wherein said electron spin resonance spectrometer is coupled to a magnet.
7. The kit of claim 1, wherein said D is selected from the group consisting of a trityl radical, a nitroso radical, tetramethylpiperidin-1-yl)oxyl (TEMPO), and a perchlorotriphenylmethyl (PTM) radical; and wherein said core moiety comprises a phosphorus-containing ring.
8. The kit of claim 1, wherein said wherein said phosphorus-containing ring is cyclotriphosphazene; wherein said G-linking moiety comprises a boronic acid moiety; and wherein said branching moiety is further attached to a linking moiety, said linking moiety links an end of said branching moiety to an additional branching moiety; and wherein: n is 6, g is 1 or 2, j is not 0.
9. A method for in-vivo, in-situ or both monitoring an amount of a molecule within a bodily fluid or interstitial tissue in a subject, comprising attaching a kit of claim 1 to said subject, wherein said attaching comprises: (a) inserting said paramagnetic tag into said bodily fluid; and (b) externally coupling said unit to a body surface of said subject, thereby monitoring an amount of the molecule within said bodily fluid.
US17/777,684 2019-11-18 2020-11-18 Minimally-invasive continuous clinical monitoring of small molecules with analytical accuracy Active 2041-03-18 US12043641B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/777,684 US12043641B2 (en) 2019-11-18 2020-11-18 Minimally-invasive continuous clinical monitoring of small molecules with analytical accuracy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962936689P 2019-11-18 2019-11-18
PCT/IL2020/051197 WO2021100042A1 (en) 2019-11-18 2020-11-18 Minimally-invasive continuous clinical monitoring of small molecules with analytical accuracy
US17/777,684 US12043641B2 (en) 2019-11-18 2020-11-18 Minimally-invasive continuous clinical monitoring of small molecules with analytical accuracy

Publications (2)

Publication Number Publication Date
US20230026678A1 US20230026678A1 (en) 2023-01-26
US12043641B2 true US12043641B2 (en) 2024-07-23

Family

ID=75981505

Family Applications (1)

Application Number Title Priority Date Filing Date
US17/777,684 Active 2041-03-18 US12043641B2 (en) 2019-11-18 2020-11-18 Minimally-invasive continuous clinical monitoring of small molecules with analytical accuracy

Country Status (2)

Country Link
US (1) US12043641B2 (en)
WO (1) WO2021100042A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995028966A1 (en) 1994-04-20 1995-11-02 Nycomed Salutar Inc Dendrimeric compounds
WO2006049913A1 (en) 2004-10-29 2006-05-11 Advanced Cardiovascular Systems, Inc. Poly(ester amide) filler blends for modulation of coating properties
US20110165087A1 (en) 2008-06-27 2011-07-07 Kao Joseph P Y Targeted delivery of imaging probes for in vivo cellular imaging
DE102010008417A1 (en) * 2010-02-18 2011-08-18 Johann Wolfgang Goethe-Universität Frankfurt am Main, 60323 High affinity multivalent chelator compounds (MCHs) and their use for the structural and functional analysis of target molecules
WO2017190144A1 (en) 2016-04-30 2017-11-02 Bvw Holding Ag Spin trap anti-adhesion hydrogels

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995028966A1 (en) 1994-04-20 1995-11-02 Nycomed Salutar Inc Dendrimeric compounds
WO2006049913A1 (en) 2004-10-29 2006-05-11 Advanced Cardiovascular Systems, Inc. Poly(ester amide) filler blends for modulation of coating properties
US20110165087A1 (en) 2008-06-27 2011-07-07 Kao Joseph P Y Targeted delivery of imaging probes for in vivo cellular imaging
DE102010008417A1 (en) * 2010-02-18 2011-08-18 Johann Wolfgang Goethe-Universität Frankfurt am Main, 60323 High affinity multivalent chelator compounds (MCHs) and their use for the structural and functional analysis of target molecules
WO2017190144A1 (en) 2016-04-30 2017-11-02 Bvw Holding Ag Spin trap anti-adhesion hydrogels

Non-Patent Citations (38)

* Cited by examiner, † Cited by third party
Title
Arnaud, J., Audfray, A., & Imberty, A. (2013). Binding sugars: from natural lectins to synthetic receptors and engineered neolectins. Chemical Society Reviews, 42(11), 4798. doi:10.1039/c2cs35435g.
Baron, A. (Apr. 27, 2022). Why is Nitinol Used in Stents?—Kellogg's Research Labs. Kellogg's Research Labs. https://www.kelloggsresearchlabs.com/2020/06/03/why-is-nitinol-used-in-stents/.
Belle A, Thiagarajan R, Soroushmehr SM, Navidi F, Beard DA, Najarian K. Big Data Analytics in Healthcare. Biomed Res Int. 2015;2015:370194. doi: 10.1155/2015/370194. Epub Jul. 2, 2015. PMID: 26229957; PMCID: PMC4503556.
Blank, A., Alexandrowicz, G., Muchnik, L., Tidhar, G., Schneiderman, J., Virmani, R. and Golan, E. (2005), Miniature self-contained intravascular magnetic resonance (IVMI) probe for clinical applications. Magn. Reson. Med., 54:105-112. https://doi.org/10.1002/mrm.20537.
Bowes WA 3rd, Corke BC, Hulka J. Pulse oximetry: a review of the theory, accuracy, and clinical applications. Obstet Gynecol. Sep. 1989;74(3 Pt 2):541-6. PMID: 2668828.
Burleson, W., & Carrara, S. (Eds.). (2014). Security and Privacy for Implantable Medical Devices. doi:10.1007/978-1-4614-1674-6.
C. Chen, P. Seifi and A. Babakhani, "A silicon-based, fully integrated pulse electron paramagnetic resonance system for mm-wave spectroscopy," 2013 IEEE MTT-S International Microwave Symposium Digest (MTT), Seattle, WA, USA, 2013, pp. 1-3, doi: 10.1109/MWSYM.2013.6697730.
Contactless Connectivity. (2013). In Eindhoven University of Technology [Presentation]. 2013 Research Retreat, Netherlands. https://assets.w3.tue.nl/w/fileadmin/content/faculteiten/ee/Onderzoek/Technologische_centra/Centre_for_Wireless_Technology/CWTe_2013_RR_Riezebos-TEConnectivity.pdf.
Córcoles, E. P., & Boutelle, M. G. (2013). Biosensors and Invasive Monitoring in Clinical Applications. SpringerBriefs in Applied Sciences and Technology. doi:10.1007/978-3-319-00360-3.
Dhar V. Big Data and Predictive Analytics in Health Care. Big Data. Sep. 2014;2(3):113-6. doi: 10.1089/big.2014.1525. PMID: 27442491.
E. Badetti, V. Lloveras, J. L. Muñoz-Gómez, R. M. Sebastián, A. M. Caminade, J. P. Majoral, J. Veciana, and J. Vidal-Gancedo. Radical Dendrimers: A Family of Five Generations of Phosphorus Dendrimers Functionalized with TEMPO Radicals. Macromolecules 2014 47 (22), 7717-7724 DOI: 10.1021/ma502062q.
E. Badetti, V. Lloveras, K. Wurst, R. M. Sebastián, A. M. Caminade, J. P. Majoral, J. Veciana, and J. Vidal-Gancedo. Synthesis and Structural Characterization of a Dendrimer Model Compound Based on a Cyclotriphosphazene Core with TEMPO Radicals as Substituents. Organic Letters 2013 15 (14), 3490-3493 DOI: 10.1021/ol401017c.
Ferri S, Kojima K, Sode K. Review of glucose oxidases and glucose dehydrogenases: a bird's eye view of glucose sensing enzymes. J Diabetes Sci Technol. Sep. 1, 2011;5(5):1068-76. doi: 10.1177/193229681100500507. PMID: 22027299; PMCID: PMC3208862.
Gault, V.A., & McClenaghan, N.H. (2009). Understanding Bioanalytical Chemistry: Principles and Applications.
Henke H, Posch S, Brüggemann O, Teasdale I. Polyphosphazene Based Star-Branched and Dendritic Molecular Brushes. Macromol Rapid Commun. May 2016;37(9):769-74. doi: 10.1002/marc.201600057. Epub Mar. 29, 2016. PMID: 27027404; PMCID: PMC4907350.
http://senseonics.com. (Jul. 14, 2015). The Sensor. Senseonics. https://web.archive.org/web/20160119042453/http:/senseonics.com/product/the-sensor.
J. Anders, J. Handwerker, M. Ortmanns and G. Boero, "A fully-integrated detector for NMR microscopy in 0.13μm CMOS," 2013 IEEE Asian Solid-State Circuits Conference (A-SSCC), Singapore, 2013, pp. 437-440, doi: 10.1109/ ASSCC.2013.6691076.
J. Handwerker, B. Schlecker, U. Wachter, P. Radermacher, M. Ortmanns and J. Anders, "28.2 A 14GHz battery-operated point-of-care ESR spectrometer based on a 0.13μm CMOS ASIC," 2016 IEEE International Solid-State Circuits Conference (ISSCC), San Francisco, CA, USA, 2016, pp. 476-477, doi: 10.1109/ISSCC.2016.7418114.
Ke C, Destecroix H, Crump MP, Davis AP. A simple and accessible synthetic lectin for glucose recognition and sensing. Nat Chem. Sep. 2012;4(9):718-23. doi: 10.1038/nchem.1409. Epub Aug. 5, 2012. PMID: 22914192.
Lloveras V, Badetti E, Wurst K, Vidal-Gancedo J. Synthesis, X-Ray Structure, Magnetic Properties, and a Study of Intra/Intermolecular Radical-Radical Interactions of a Triradical TEMPO Compound. Chemphyschem. Oct. 26, 2015;16 (15):3302-7. doi: 10.1002/cphc.201500462. Epub Aug. 26, 2015. PMID: 26489060.
Luijf YM, Mader JK, Doll W, Pieber T, Farret A, Place J, Renard E, Bruttomesso D, Filippi A, Avogaro A, Arnolds S, Benesch C, Heinemann L, DeVries JH; AP@home consortium. Accuracy and reliability of continuous glucose monitoring systems: a head-to-head comparison. Diabetes Technol Ther. Aug. 2013;15(8):722-7. doi: 10.1089/dia.2013.0049. Epub May 7, 2013. PMID: 23650900; PMCID: PMC3746288.
Machine translation of DE-102010008417-A1 (Year: 2011). *
Michael J Davies, Detection and characterization of radicals using electron paramagnetic resonance (EPR) spin trapping and related methods, Elsevier, available on line May 19, 2016 (Year: 2016). *
PCT International Preliminary Report on Patentability for International Application No. PCT/IL2020/051197, issued May 17, 2022, 7pp.
PCT International Search Report for International Application No. PCT/IL2020/051197, mailed Feb. 11, 2021, 6pp.
Schmid, C., Haug, C., Heinemann, L., & Freckmann, G. (2013). System Accuracy of Blood Glucose Monitoring Systems: Impact of Use by Patients and Ambient Conditions. Diabetes Technology & Therapeutics, 15(10), 889-896. doi:10.1089/dia.2013.0047.
Smith, John. (2006). The Pursuit of Noninvasive Glucose: Hunting the Deceitful Turkey.
Soares DP, Law M. Magnetic resonance spectroscopy of the brain: review of metabolites and clinical applications. Clin Radiol. Jan. 2009;64(1):12-21. doi: 10.1016/j.crad.2008.07.002. Epub Aug. 30, 2008. PMID: 19070693.
Stoeckel D, Pelton A, Duerig T. Self-expanding nitinol stents: material and design considerations. Eur Radiol. Feb. 2004;14(2):292-301. doi: 10.1007/s00330-003-2022-5. Epub Sep. 3, 2003. PMID: 12955452.
Surman F, Riedel T, Bruns M, Kostina NY, Sedláková Z, Rodriguez-Emmenegger C. Polymer brushes interfacing blood as a route toward high performance blood contacting devices. Macromol Biosci. May 2015;15(5):636-46. doi: 10.1002/mabi.201400470. Epub Jan. 21, 2015. PMID: 25644402.
Suzen S, Gurer-Orhan H, Saso L. Detection of Reactive Oxygen and Nitrogen Species by Electron Paramagnetic Resonance (EPR) Technique. Molecules. Jan. 21, 2017;22(1):181. doi: 10.3390/molecules22010181. PMID: 28117726; PMCID: PMC6155876.
Turner, W. J., Xiao, Z., Wu, S., Beck, B. L., Bashirullah, R., & Mareci, T. H. (2010). Digitally controlled μ-chip capacitor array for an implantable multiple frequency coil. In Proc. 18th Annu. Meeting ISMRM (Stockholm, Sweden) (p. 424).
Wang, M.J. & Tsai W.-B. Biomaterials in Blood-Contacting Devices: Complications and Solutions. Nova Science Publishers, New York 2010.
Woflson, H., Ahmad, R., Twig, Y., Williams, B., & Blank, A. (2015). A Magnetic Resonance Probehead for Evaluating the Level of Ionizing Radiation Absorbed in Human Teeth. Health Physics, 108(3), 326-335. doi: 10.1097/hp.0000000000000187.
Wolfson, H., Ahmad, R., Twig, Y. et al. A Miniature Electron Spin Resonance Probehead for Transcutaneous Oxygen Monitoring. Appl Magn Reson 45, 955-967 (2014). https://doi.org/10.1007/s00723-014-0593-8.
X. Yang and A. Babakhani, "A Single-Chip Electron Paramagnetic Resonance Transceiver in 0.13-μ m SiGe BiCMOS," in IEEE Transactions on Microwave Theory and Techniques, vol. 63, No. 11, pp. 3727-3735, Nov. 2015, doi: 10.1109/ TMTT.2015.2481895.
Yang X, Pan X, Blyth J, Lowe CR. Towards the real-time monitoring of glucose in tear fluid: holographic glucose sensors with reduced interference from lactate and pH. Biosens Bioelectron. Jan. 18, 2008;23(6):899-905. doi: 10.1016/j.bios.2007.09.016. Epub Sep. 29, 2007. PMID: 18060763.
Zgadzai O, Twig Y, Wolfson H, Ahmad R, Kuppusamy P, Blank A. Electron-Spin-Resonance Dipstick. Anal Chem. Jul. 3, 2018;90(13):7830-7836. doi: 10.1021/acs.analchem.8b00917. Epub Jun. 13, 2018. PMID: 29856211.

Also Published As

Publication number Publication date
WO2021100042A1 (en) 2021-05-27
US20230026678A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
Issadore et al. Miniature magnetic resonance system for point-of-care diagnostics
Beckonert et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts
Zhang et al. Advances in NMR-based biofluid analysis and metabolite profiling
US8836334B2 (en) NMR systems for in vivo detection of analytes
Sang et al. A portable device for rapid detection of human serum albumin using an immunoglobulin-coating-based magnetoelastic biosensor
Stevens et al. HyperCEST detection of a 129Xe‐based contrast agent composed of cryptophane‐A molecular cages on a bacteriophage scaffold
US20190313977A1 (en) Sensor Systems
Baute et al. Carboxylate binding in copper histidine complexes in solution and in zeolite Y: X-and W-band pulsed EPR/ENDOR combined with DFT calculations
Jaroszewicz et al. Sensitivity enhancement by progressive saturation of the proton reservoir: A solid-state NMR analogue of chemical exchange saturation transfer
Palaniappan et al. Molecular sensing using hyperpolarized xenon NMR spectroscopy
US20160154077A1 (en) Msc-selmqc method for simultaneous mapping of polyunsaturated fatty acids, lactate and choline in high fat tissues
Kaminker et al. Overhauser dynamic nuclear polarization studies on local water dynamics
Chugh et al. Magnetic particle spectroscopy with one-stage lock-in implementation for magnetic bioassays with improved sensitivities
WO2014099463A1 (en) System and method for sensitivity-enhanced multi-echo chemical exchange saturation transfer (mecest) magentic resonance imaging
Yu et al. Highly fluorinated metal complexes as dual 19 F and PARACEST imaging agents
Huber et al. Multichannel digital heteronuclear magnetic resonance biosensor
Luo et al. New frontiers in in vitro medical diagnostics by low field T2 magnetic resonance relaxometry
Demas et al. Magnetic resonance for in vitro medical diagnostics: superparamagnetic nanoparticle-based magnetic relaxation switches
US10613169B2 (en) Methods for monitoring changes in the core of lipoprotein particles in metabolism and disease
Yang et al. Practical aspects of copper ion-based double electron electron resonance distance measurements
US12043641B2 (en) Minimally-invasive continuous clinical monitoring of small molecules with analytical accuracy
CA2401486C (en) Method for the esr-spectroscopic detection of changes in the transport properties of albumin in an albumin-containing sample, an esr spectrometer for carrying out said method, anduse of the method for diagnostic purposes and for controlling albumin-containing preparations
You et al. Ultrasensitive and fast detection of pathogens using Europium-containing polystyrene nanospheres in a homemade portable NMR diagnostic system
Lu et al. Magnetically detected protein binding using spin-labeled slow off-rate modified aptamers
US20130224073A1 (en) Device for detection of magnetic nanoparticle aggregation or disaggregation

Legal Events

Date Code Title Description
AS Assignment

Owner name: UNIVERSITAT ULM, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ANDERS, JENS;REEL/FRAME:059946/0022

Effective date: 20191031

Owner name: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED, ISRAEL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UNIVERSITAT STUTTGART;REEL/FRAME:059946/0014

Effective date: 20220517

Owner name: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED, ISRAEL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BLANK, AHARON;REEL/FRAME:059945/0979

Effective date: 20220509

Owner name: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED, ISRAEL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VIDAL GANCEDO, JOSE;LLOVERAS MONSERRAT, VEGA;REEL/FRAME:059945/0955

Effective date: 20220511

Owner name: UNIVERSITAT STUTTGART, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UNIVERSITAET ULM;REEL/FRAME:060110/0261

Effective date: 20191111

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: AWAITING TC RESP., ISSUE FEE NOT PAID

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE